GDRX Goodrx Holdings Inc

$4.68

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

About Goodrx Holdings Inc

GoodRx Holdings, Inc. provides information and tools that allow consumers to compare prices and save when buying prescription drugs in the United States. The company is headquartered in Santa Monica, California.

Website: https://www.goodrx.com

Sector
TECHNOLOGY
Industry
SERVICES-COMPUTER PROCESSING & DATA PREPARATION
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1809519
Address
233 WILSHIRE BLVD., SUITE 990, SANTA MONICA, CA, US
Valuation
Market Cap
$1.72B
P/E Ratio
112.12
PEG Ratio
nan
Price to Book
2.37
Performance
EPS
$0.04
Dividend Yield
—
Profit Margin
2.07%
ROE
2.20%
Technicals
50D MA
$4.64
200D MA
$5.92
52W High
$9.26
52W Low
$3.82
Fundamentals
Shares Outstanding
107M
Target Price
$6.62
Beta
1.26

GDRX EPS Estimates vs Actual

● Estimated
● Actual

GDRX News & Sentiment

Apr 08, 2025 • Zacks Commentary BULLISH
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform
GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Mar 06, 2025 • Benzinga NEUTRAL
FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment - ARS Pharmaceuticals ( NASDAQ:SPRY )
FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential.
Mar 05, 2025 • GlobeNewswire NEUTRAL
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg ( epinephrine nasal spray ) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children ...
Mar 05, 2025 • Benzinga NEUTRAL
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg ( epinephrine nasal spray ) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms - ARS Pharmaceuticals ( NASDAQ:SPRY )
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc.
Feb 27, 2025 • Motley Fool SOMEWHAT-BULLISH
GoodRx ( GDRX ) Q4 2024 Earnings Call Transcript
GDRX earnings call for the period ending December 31, 2024.
Feb 27, 2025 • Benzinga SOMEWHAT-BULLISH
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales - GoodRx Holdings ( NASDAQ:GDRX )
GoodRx Q4 revenue rose 1% YoY to $198.6M, missing guidance and estimates. Adjusted EPS of $0.09 missed the $0.10 consensus. 2024 prescription transactions revenue grew 5% to $577.5M, while subscription revenue fell 8% due to the Kroger Savings Club phaseout.
Sentiment Snapshot

Average Sentiment Score:

0.166
50 articles with scored sentiment

Overall Sentiment:

Bullish

GDRX Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.09
  • Estimate: $0.10
  • Whisper: —
  • Surprise %: -6.2%
Nov 07, 2024
Sep 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.08
  • Estimate: $0.09
  • Whisper: —
  • Surprise %: -11.1%
Aug 08, 2024
Jun 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.08
  • Estimate: $0.09
  • Whisper: —
  • Surprise %: -11.1%
May 09, 2024
Mar 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $0.08
  • Estimate: $0.08
  • Whisper: —
  • Surprise %: 0.0%
Feb 29, 2024
Dec 31, 2023 (Pre market)
0.01 Surprise
  • Reported EPS: $0.08
  • Estimate: $0.07
  • Whisper: —
  • Surprise %: 14.3%
Nov 09, 2023
Sep 30, 2023 (Pre market)
0.0 Surprise
  • Reported EPS: $0.06
  • Estimate: $0.06
  • Whisper: —
  • Surprise %: 0.0%
Aug 09, 2023
Jun 30, 2023 (Pre market)
0.01 Surprise
  • Reported EPS: $0.07
  • Estimate: $0.06
  • Whisper: —
  • Surprise %: 16.7%
May 10, 2023
Mar 31, 2023 (Pre market)
0.01 Surprise
  • Reported EPS: $0.07
  • Estimate: $0.06
  • Whisper: —
  • Surprise %: 16.7%
Feb 28, 2023
Dec 31, 2022 (Post market)
0.02 Surprise
  • Reported EPS: $0.07
  • Estimate: $0.05
  • Whisper: —
  • Surprise %: 40.0%

Financials